Dr. Myers started at the Cleveland Clinic in June of 2018. His role is new to the clinic and encompasses leadership of the ambulatory practices, community internal medicine, geriatrics, community pediatrics, family medicine, hospital medicine, express care, post-acute medicine, ambulatory pharmacy, medical care@home, distance health, the ACO structure, the 6000 member clinically integrated network, wellness, integrative medicine, executive health, three residency programs, ambulatory behavioral medicine, the employee health plan, as well as the center for value based research.

Prior to joining the clinic, Dr. Myers served as Chief Medical Officer and Chief Operating Officer of Texas Health Physicians Group, a 1000-member multispecialty group affiliated with Texas Health Resources. Dr. Myers also served as chair of clinical integration for a 3000 member joint venture CIN with UTSW called Southwestern Health Resources.

A New York City native, Myers is board-certified in family medicine and was in private practice in Oklahoma for more than 10 years. He also served on faculty in the University of Oklahoma Obstetrics and Gynecology department for 7 years teaching obstetrics before moving to Dallas in 2010 to serve as chief medical officer and senior vice president for Methodist Health System. He currently serves as Chair of the American Hospital Association board level Committee for Clinical Leadership.
Myers is an accomplished clinician, business leader, author and humanitarian. He has earned numerous professional credentials including the status of Fellow with the American College of Healthcare Executives, The American Institute of Healthcare Quality and the American Association of Family Physicians. He holds additional board certification in healthcare quality management and patient safety, and he’s a certified professional in healthcare risk management.

Myers received his undergraduate degree from Centenary College of Louisiana in Shreveport, where he graduated from Louisiana State University Medical Center. He completed his residency with In His Image Family Practice Residency at Hillcrest Medical Center in Tulsa, Okla., and has completed fellowship work at the University of Oklahoma Obstetrics and Gynecology Department. He also completed a Masters in Health Care Management from Harvard University.

Contact Information:

ALISTAIR ERSKINE, MD is the Chief Digital Health Officer at Massachusetts General Brigham, teaching hospitals for Harvard Medical School.  He is responsible for sequencing innovative technologies, harmonizing data across the clinical care, research and health plan enterprise, and aligning digital patient experience with emerging patient consumerism trends.  Dr. Erskine leads the Digital Health department responsible the design and configuration of Mass General Brigham's clinical information systems and virtual care services.  He also leads the Enterprise Data & Digital Health program, a targeted five-year initiative to advance foundational investments in digital patient and clinician experience, system operations, and clinical care to enable Mass General Brigham to engage across local, national and global markets. 
 
Prior to Mass General Brigham, Dr. Erskine was Geisinger Health’s Chief Informatics Officer and oversaw Geisinger’s Unified Data Architecture, a hedged data management environment powered by Hadoop/Big Data and traditional relational database systems. In previous roles, he was appointed to the Virginia Governor’s Health Information Technology Commission by Executive Order and was a voting member of the Health Information Technology Standards Committee.  He presents and publishes on the topic of digital health, clinical transformation and virtual care in peer-reviewed literature and serves on Boards of several companies.  

Dr. Erskine trained at Brown University and Virginia Commonwealth University Health System and is triple Board-Certified in Internal Medicine, Clinical Informatics and Pediatrics.  He completed a two-year degree program at MIT Sloan School of Management, with a specialization in Business Analytics and Artificial Intelligence. He has been practicing hospital medicine for 15 years and teaches at Harvard Medical School. 
 

Contact Information:

Angela Yochem is EVP & Chief Digital and Technology Officer for Novant Health, a super-regional healthcare system with one of the largest medical groups in the US. She and her teams deliver the world-class consumer capabilities, differentiating technologies, and advanced clinical solutions that allow the high-growth system to provide remarkable patient care.

Angela has served as EVP/CIO at Rent-A-Center, Global CIO at BDP International, Global CTO at AstraZeneca, and divisional CIO at Dell. She’s held tech exec roles at Bank of America and SunTrust, and held senior technology roles at UPS and IBM. In these roles, she built B2B digital product lines, grew digital retail channels (B2C), created technical services lines of business, and transformed global technology capabilities. 

Angela is an Independent Director with Zurich American Insurance Group, and has been a Director for the Federal Home Loan Bank of Pittsburgh, BDP Transport, BDP Global Services Asia and Europe, and Rocana, with experience on Audit, Enterprise Risk, Operational Risk, and Governance/Policy committees. She remains an Entrepreneur in Residence, Mentor, and Advisor for venture groups and incubators on both US coasts. Angela serves on the board of Freedom School Partners, a non-profit committed to promoting literacy in the Charlotte area, and co-chairs the executive team of the Go Red for Women Charlotte organization, part of the American Heart Association. She is a Trustee of the Charlotte Regional Business Initiative, and is an advisory board member for the American Hospital Association Innovation Council, the University of Tennessee Electrical Engineering and Computer Science department, and the University of North Carolina Charlotte College of Computing and Informatics. 

Angela has a Bachelor of Music from DePauw University and a Master of Science in Computer Science from the University of Tennessee, holds three US Patents and is an author with Addison-Wesley and Prentice-Hall. 
 

Contact Information:

Anne Klibanski, M.D. is the President and Chief Executive Officer of Mass General Brigham, formerly Partners HealthCare. Dr. Klibanski leads the largest private employer in the Commonwealth of Massachusetts, setting and implementing strategic priorities focused on patient care and innovation. Prior to her current appointment, Dr. Klibanski served as the Chief Academic Officer and Harvard Medical School Faculty Dean for Academic Programs. In this role, she was responsible for an annual research enterprise of more than $1.8 billion, as well as graduate medical education and continuing professional development. She led multiple system-wide efforts aimed at clinical and research collaboration and oversaw advances in educational strategic initiatives. Dr. Klibanski also served as the Chief of Neuroendocrine at Massachusetts General Hospital and is recognized internationally for her high impact research in neuroendocrine disorders and pituitary tumors.

Dr. Klibanski received her B.A., magna cum laude in literature from Barnard College and her M.D. from New York University Medical Center. She is the Laurie Carrol Guthart Professor of Medicine at Harvard Medical School.
 

Contact Information:

Brian G. Donley, M.D. Dr. Brian Donley began his new role as Chief Executive Officer of Cleveland Clinic London in February 2018. Prior to this appointment, he was the Chief of Staff and Chief of the Clinical Enterprise for the Cleveland Clinic Health System beginning in January 2015. Previous to that, he served as President of Regional Operations for the Cleveland Clinic Health System overseeing 10 Regional Hospitals and eighteen Family Health Centers. Dr. Donley is Professor of Surgery at the Cleveland Clinic Lerner College of Medicine. He attended the University of Notre Dame for his undergraduate studies, graduating Phi Beta Kappa. He graduated With Distinction from the University of Michigan Medical School and completed his residency in orthopaedic surgery at the University of Michigan. Dr. Donley completed a fellowship in orthopaedic foot and ankle surgery at the Campbell Clinic in Memphis, TN. He also attended Harvard Business School completing the Advanced Management Program. He joined Cleveland Clinic’s Orthopaedic & Rheumatologic Institute in 1996, serving in various roles over the years, including Vice Chairman of the Department of Orthopaedics, Director of the Foot and Ankle Fellowship, and Director of Research and Education for Foot and Ankle Surgery. He was team physician for the Cleveland Browns professional football team and has been an orthopaedic consultant for many professional sports teams. In 2007, he was chosen to the prestigious American-British-Canadian travelling fellowship that provided an opportunity for Dr Donley to visit many NHS trusts throughout the UK learning and improving his clinical and administrative skills. Dr. Donley was a member of the development team for the Salto Talaris total ankle prosthesis and performed the first surgery in the world with this ankle implant at Cleveland Clinic in 2006. He holds three patents and has over 100 scientific publications.

Contact Information:

Brian Rubin, MD, PhD is Professor and Chair of Pathology, and Director of Soft Tissue Pathology of the Robert J. Tomsich Pathology and Laboratory Medicine Institute at the Cleveland Clinic. He received his PhD in molecular biology and his MD from Cornell University Medical College. He did his residency in Anatomic Pathology at Brigham and Women’s Hospital and received fellowship training in soft tissue pathology, bone pathology, and cancer genetics.
 
Dr. Rubin has dedicated his career to a better understanding of the diagnosis and classification of soft tissue neoplasms, especially sarcomas, where he is a prominent figure nationally and internationally. He is widely regarded as a thought leader in the field and is a founding member of the International Society of Bone and Soft Tissue Pathology. His laboratory is focused on understanding the pathogenesis of sarcomas with the major aim of developing targeted therapies. Dr. Rubin has published over 200 peer reviewed journal articles and is the author of numerous reviews and book chapters. He was a member of the working group that authored the WHO Classification of Tumours of Bone and Soft Tissue in 2002 and 2012. He is well known for his work on gastrointestinal stromal tumor (GIST) and other cancers such as melanoma that are driven by oncogenically-activated KIT receptor tyrosine kinase. His group also characterized a novel gene fusion in epithelioid hemangioendothelioma (EHE), a sarcoma with endothelial differentiation. This latest development has allowed them to initiate studies of EHE biology with the goal of developing targeted therapies to treat EHE. Finally, Dr. Rubin has led his team in the Robert J. Tomsich Pathology and Laboratory Medicine Institute to launch, expand, and maintain SARS-CoV-2 (COVID) testing during the recent unprecedented pandemic.
 

Contact Information:

Charis Eng, MD, PhD, is Sondra J. and Stephen R. Hardis Endowed Chair of Cancer Genomic Medicine, an ACS Clinical Research Professor and the inaugural Chairwoman of the Cleveland Clinic’s Genomic Medicine Institute and Director of its clinical component, the Center for Personalized Genetic Healthcare.  As such, she leads the genomics efforts across the global enterprise.  Dr. Eng also is Professor and Vice Chair of the Department of Genetics and Genome Sciences at Case Western Reserve University School of Medicine. A physician-scientist, She is the go-to person in genomics-informed precision healthcare. With over 500 peer-reviewed articles, she is an elected member of the National Academy of Medicine, and recipient of the American Cancer Society Medical of Honor, among numerous awards. Last year, Dr. Eng was named as the top 0.01% of all scientists in the world across all scientific topics. She has served as advisory to DHHS Secretary’s Committee on Genetics, Health & Society.  Dr. Eng is founder and pro bono Chief Medical Officer of Family Care Path, Inc. and Covariance, LLC.
 

Contact Information:

Dr. Eric Fung is Vice President, Clinical Development at GRAIL, where he leads several clinical development programs in support of the development of a blood-based multi-cancer detection test. Dr. Fung has previously held clinical development and R&D leadership roles at Affymetrix, Vermillion, Ciphergen, and Roche Molecular Diagnostics. Dr. Fung has led clinical trials leading to FDA clearance of multiple IVD products. Dr. Fung received his MD, PhD from the Johns Hopkins University School of Medicine.

Contact Information:

Eric Walli is the Division Manager of Regional Planning for American Honda Motor, Inc., with responsibility for the long-term strategy development for Honda’s regional companies covering automotive, powersports and power equipment businesses. Walli is also responsible for creating and leading Honda North America’s sustainability office.
 
Prior to this, Walli was the Department Manager of Strategic Engineering where he led a newly-formed organization designed to promote manufacturing-based research and innovation along both technical and business domains.
 
After joining Honda in January 1995, Walli served on the engineering staff where he was responsible for the electrical design of equipment used to manufacture automobiles in the Weld and Stamping areas of OEM production. He became an engineering coordinator in 1998 and moved to Strategic Planning in 2002 where he was responsible for analyzing and measuring manufacturing metrics in order to identify improvement and flexibility opportunities throughout Honda’s automobile production facilities.
 
In 2004, Walli was promoted to Assistant Manager of Strategic Planning for Honda’s non-synchronous parts business for North America automobile production.
 
He became a Manager in 2007 and was responsible for Honda North America’s automobile production allocation. Walli then led the development of production technology strategy for Honda North America, Inc., fostering collaboration across manufacturing, design and procurement divisions.
 
A native of Logan, Ohio, Walli is a graduate of The Ohio State University, where he earned a bachelor’s degree in electrical engineering as well as master’s degree in business administration from the Fisher College of Business.
 
In addition to his role at American Honda Motor, Walli serves on the Mid-Ohio Regional Planning Commission’s (MORPC) Sustainability Advisory Board & Attributable Funds Committee, the Ohio Fuel Cell Coalition (OFCC) Board, and the Grandview Heights Parks and Recreation Advisory Board.  He also serves as a guest lecturer at The Ohio State University Fisher College of Business.
 

Contact Information:

Gail K. Boudreaux is President & CEO of Anthem, Inc., a Fortune 50 company and leading health benefits provider, serving nearly 41 million insured members through its affiliated health plans. In total, Anthem serves over 79 million lives across 27 states through its broad portfolio of health insurance and services subsidiaries.

Throughout her more than three decades in the healthcare industry, Ms. Boudreaux has established an outstanding record of successfully leading multi-billion dollar businesses. As former CEO of United Healthcare, Ms. Boudreaux led the largest business division of UnitedHealth Group, where she had responsibility for approximately $120 Billion in revenue and managed more than 60,000 employees serving 45 million consumers. Prior to United Healthcare, Ms. Boudreaux served as Executive Vice President of Health Care Services Corporation and earlier as President of Blue Cross/Blue Shield of Illinois. Ms. Boudreaux currently serves on the board of directors for Zimmer Biomet Holdings. She earned a bachelor’s degree with honors from Dartmouth College and an MBA with distinction from Columbia Business School.

Gail has been named as one of Fortune Magazine’s Most Powerful Women in Business…and featured by Forbes as one of 100 Most Powerful Women in the World. Additionally, she has been named by Modern Healthcare as one of the 100 Most Influential People in Healthcare, and she also received the 2018 Billie Jean King Leadership Award.

Contact Information:

Gianrico Farrugia, M.D., president and CEO of Mayo Clinic, leads one of the largest not-for-profit, academic health systems in the U.S., with a 70,000-person workforce and $14 billion in annual revenue. Mayo Clinic focuses on patients with serious or complex illnesses, caring for more than 1.2 million unique patients each year from all 50 states and nearly 140 countries. Mayo Clinic is ranked No. 1 in the nation by U.S. News & World Report. 

Prior to his appointment as president and CEO, Dr. Farrugia served as CEO of Mayo Clinic in Florida. Under his leadership, Mayo Clinic in Florida established itself as the destination medical center for the Southeast. He also led Mayo Clinic’s Center for Individualized Medicine, which brings genomics into routine clinical care, and co-founded Mayo Clinic’s Center for Innovation. He is a member of the Mayo Clinic Board of Trustees and Mayo Clinic Board of Governors, and is a professor of medicine and physiology, Mayo Clinic College of Medicine and Science.

Dr. Farrugia has been a Mayo Clinic physician for 30 years. He is jointly appointed in the Division of Gastroenterology and Hepatology, Department of Internal Medicine, and the Department of Physiology and Biomedical Engineering. He completed his undergraduate training at St. Aloysius College and earned his medical degree from the University of Malta Medical School.

Dr. Farrugia is immediate past president of the American Neurogastroenterology and Motility Society. He is the co-author of “Think Big, Start Small, Move Fast: A Blueprint for Transformation From the Mayo Clinic Center for Innovation,” a book highlighting the need for change in the delivery of health care. In addition, he has published more than 300 articles on genomics and the treatment of disorders of gastrointestinal motility. Dr. Farrugia is a member of the Minnesota Business Partnership and is a healthcare governor at the World Economic Forum.

Contact Information:

Ginger Christ is the post-acute care and staffing reporter for Modern Healthcare and is based in Northeast Ohio, where she grew up. Most recently, she wrote about healthcare and transportation for The (Cleveland) Plain Dealer. Before that, she covered real estate, manufacturing and business news for local newspapers and national magazines, starting in 2007. She is the co-founder of the Cleveland chapter of the Association of Health Care Journalists, is on the board of the Press Club of Cleveland and is involved in various efforts to connect and support journalists in her community.

Contact Information:

Heath Rigsby is Vice President and Commercial Leader of the Out of Home business for The Clorox Company, a leading multinational manufacturer and marketer of consumer and professional products with about 8,800 employees worldwide and sales of $6.7 billion.

Since joining Clorox in 2001, Heath has held domestic and international sales, marketing and general management positions in both the consumer and professional markets including most recently Vice President of International Sales and Vice President of Professional Products Sales. In his current role, Heath leads the newly formed Clorox Out of Home group, a multi-functional team charged with building alliances and partnerships with global multinational organizations.

Prior to joining Clorox, Heath worked for Procter & Gamble. He has an M.B.A. from the University of Tennessee and a B.S. from The University of North Carolina at Chapel Hill.

Contact Information:

Jacqueline Law, Ph.D., is the VP & Global Head of Personalized Healthcare Data Science at Genentech/Roche. In this role, Jacqueline leads a team of data scientists with expertise in omics, imaging and Real-World Data (RWD) analysis. The RWD team is responsible for RWD strategy and implementation for late stage development, medical affairs and market access across all therapeutic areas including oncology, neuroscience, infectious disease, inflammation and ophthalmology. Law has been with Genentech/Roche for 16 years and has led quantitative science teams in both Pharma and DIA divisions. Law received her Ph.D. in Biostatistics from the University of California, Los Angeles.

Contact Information:

As Chief Medical Officer of Pfizer, Mace Rothenberg leads Pfizer’s Worldwide Medical & Safety organization that is responsible for ensuring that patients, physicians, and regulatory agencies are provided with information on the safe and appropriate use of Pfizer medications.  Dr. Rothenberg is also a member of Pfizer’s Portfolio Strategy and Investment Committee, Worldwide Research, Development, and Medical Leadership Team, and Blueprint Leaders Forum.  Outside of his responsibilities at Pfizer, Dr. Rothenberg co-chairs the Life Sciences Consortium of the CEO Roundtable on Cancer and is a member of the NYU School of Medicine’s Alumni Board of Governors.

Prior to becoming Pfizer’s CMO, Dr. Rothenberg was Head of Clinical Development & Medical Affairs for Oncology from 2008 to 2016 and Chief Development Officer for Oncology from 2016 to 2018, During that period, Dr. Rothenberg’s organization was responsible for the successful development and regulatory approval of 11 new cancer medicines.  Prior to joining Pfizer, Dr. Rothenberg spent 25 years in academia where he focused on early-stage drug development, clinical trial design, and the coordinated laboratory-clinical evaluation of new therapies for gastrointestinal cancers.

Dr. Rothenberg is the recipient of the first Craig Saxton Lifetime Achievement Award from Pfizer, the Lane W. Adams Quality of Life Award from the American Cancer Society honoring him as one of the nation's top cancer caregivers, and the Statesman Award from the American Society of Clinical Oncology honoring him for more than 20 years of service to the organization, the specialty of oncology and cancer patients.  He is a Fellow of the American College of Physicians and the American Society of Clinical Oncology.

Dr. Rothenberg received his BA magna cum laude from the University of Pennsylvania in 1978 and his MD from the New York University School of Medicine in 1982.  He received his post-graduate training in Internal Medicine at Vanderbilt University and in Medical Oncology at the National Cancer Institute. Dr. Rothenberg served on the faculties of the University of Texas Health Science Center–San Antonio (1991-1998) and Vanderbilt University (1998-2008).
 

Contact Information:

Matthew Kull is the enterprise Chief Information Officer at Cleveland Clinic, a global medical system that includes a main campus, 10 regional hospitals, 18 family health centers, and facilities in Florida, Nevada, Toronto, Abu Dhabi and London. He serves with responsibility for all aspects of the Clinic’s enterprise technology.
 
Prior to his role at the Cleveland Clinic, Mr. Kull served as Senior Vice President and Chief Information Officer for Parkland Health & Hospital System in Dallas, Texas. While at Parkland, Matthew lead the technology efforts within the construction of Parkland’s new, fully digital, 2.7 million square foot hospital campus. Upon its opening the new campus was lauded as one of the most technically advanced hospital’s in the world.
 
Mr. Kull is a recognized technology expert with a history of developing innovative and transformational technology strategies for organizations of all sizes across multiple industries. His experience spans over twenty years and a variety of healthcare settings including hospitals, pharmacies, regional oncology and disease management institutions. Mr. Kull has held senior leadership positions at internationally recognized enterprises including AmerisourceBergen, McKesson, and NTT. He has also spent a number of years as a management consultant providing strategic guidance to companies across multiple industries. Notable clients include Shoppers Drug Mart, Accenture, Alcon Laboratories, OncoMed, Eurocopter, Thompson Reuters, TXU Energy, Suez Corporation, Citi Group, and Nokia.
 
Mr. Kull holds a Master of Business Administration degree from Southern Methodist University in Dallas, Texas. He is a Certified Healthcare Chief Information Officer (CHCIO) and maintains professional affiliations with College of Healthcare Information Management Executives (CHIME) and Healthcare Information and Management Systems Society (HIMSS). He has won numerous awards, including Dallas Business Journal’s CIO of the Year.

Contact Information:

Since joining CNBC in April 2014, Tirrell has covered the development of new medicines for Alzheimer’s, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika to the COVID-19 pandemic. Her reporting has also chronicled the massive set of trials seeking to hold the drug industry accountable for the opioid epidemic, market failures that have led to life-threatening drug shortages, and the ongoing fight over the cost of medicines.

Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.

Tirrell holds a master’s degree in journalism from Northwestern University and a bachelor’s degree in English and music from Wellesley College.

Follow her on Twitter @megtirrell.
 

Contact Information:

Mudit is a Founding General Partner of Strategic Healthcare Investment Partners (S.H.I.P.), and the CEO and co-founder of NuXcel, a medical device accelerator. Mudit also co-founded and serves as Chairman of the Board of ShiraTronics, Inc., a NuXcel spin off company.  

Mudit has over two decades of medical device industry experience across company formation, R&D, and business development. In addition to his private venture capital experiences at S.H.I.P, and Synergy Life Science Partners, Mudit also brings a strategic investment perspective based on his tenure at Johnson and Johnson Development Corporation. 

Mudit has served on the boards of several medical device companies, from early to commercial growth stage, resulting in successful IPOs and M&A transactions. Mudit currently serves on the boards of CVRx, Inc., ShiraTronics, Inc., Neochord, Inc., NuXcel, and Noctrix, Inc. Some of his prior investments/board responsibilities include Inspire Medical Systems (NYSE: INSP), Irhythm Technologies (NSDQ:IRTC), Aptus Endosystems (Acqd. by Medtronic), CardioMEMS (Acqd. by St. Jude Medical), Impres Medical (Acqd. by J&J), and Neuspera,Inc.  

Mudit also serves on the Board of Visitors of the Graduate School at Duke University, External Advisory Board of John Hopkins University Center for Bioengineering Innovation and Design, and on the Board of One Heart Health, a healthcare non-profit, focused on providing healthcare access to pediatric populations in underprivileged geographies.  

Prior to his investing career, Mudit held operational roles in the Cardiac Rhythm Management Division of Guidant Corporation, and played a key role in developing novel device technologies for heart failure, remote cardiac monitoring, and cardiac ablation. Mudit holds eight issued patents and has authored several peer reviewed publications.

Mudit graduated with a B.E. in Electrical Engineering from REC, Nagpur, India, where he was a gold medal recipient for academic achievements. He received his Ph.D. in Biomedical Engineering from Duke University, and his M.B.A. from the Wharton School, University of Pennsylvania.
 

Contact Information:

Dr. Pampee Young, Chief Medical Officer of Biomedical Services of the American Red Cross. Dr. Young provides medical guidance, vision, and strategic direction focused on donor and patient safety objectives for a team of 35 physicians. She also provides leadership and support to the divisions of Scientific Affairs and Transfusion Innovations which are engaged in collaborative research with industry, government agencies and academic centers. Prior to joining the Red Cross, Dr. Young served as a tenured Professor and Medical Director of Transfusion Medicine and the Stem Cell Laboratory at Vanderbilt University Medical Center in Nashville. She has published over 100 publications and invited reviews and serves on several advisory and editorial boards.

Contact Information:

Rajeev Venkayya is President of the Global Vaccine Business Unit at Takeda Pharmaceuticals, where he leads a team that is developing vaccines for dengue, norovirus and Zika, and supplying pandemic influenza and other vaccines in Japan. He is an independent member of the board of the Coalition for Epidemic Preparedness Innovations (CEPI), which is funding several COVID-19 vaccine development programs. He is also on the board of the International AIDS Vaccine Initiative (IAVI).

Dr. Venkayya previously served at the White House as Special Assistant to the President for Biodefense. In this role, he was the principal author of the National Strategy for Pandemic Influenza (2005), and he led the development and execution of the companion Implementation Plan. His team conceived the strategy of early, coordinated implementation of non-pharmaceutical interventions to slow the spread of a pandemic virus, now known as the “flattening the curve,” that was described in the US Government’s guidelines on community mitigation of pandemic influenza. 

Prior to joining Takeda, Dr. Venkayya served as Director of Vaccine Delivery at the Bill & Melinda Gates Foundation, where he was responsible for the foundations top two priorities of polio eradication and the introduction of new vaccines into developing countries through Gavi, the Vaccine Alliance. He served on the board of Gavi. 

Dr. Venkayya trained and served on the faculty in Pulmonary & Critical Care Medicine at the University of California, San Francisco. He was a resident and Chief Medical Resident in Internal Medicine at the University of Michigan. He received his M.D. from the Northeast Ohio Universities College of Medicine, where he was inducted into the Alpha Omega Alpha honorary medical society.

Contact Information:

Dr. Richard Zane currently serves as the George B. Boedecker Professor and Chair of the Department of Emergency Medicine at the University of Colorado School of Medicine, Professor of Health Administration at the University of Colorado Business School and Chief Innovation Officer at UCHealth.

Dr. Zane completed medical school at Temple University in Philadelphia followed by residency training in emergency medicine at the Johns Hopkins School of Medicine. Following residency, Dr. Zane joined the faculty at Johns Hopkins as Assistant Chief of Service. In 1998, Dr. Zane joined the faculty at Harvard Medical School and Brigham and Women’s Hospital in Boston.

While in Boston, with funding from the Agency for Healthcare Quality and Research, Department of Homeland Security and Assistant Secretary for Preparedness and Response, he formed collaborative industry partnerships to develop tools for preparedness and response to mass casualty care and disaster. These tools have been used domestically and across the globe for events including the earthquake in Haiti, Hurricane Katrina, the Japan earthquake and tsunami and the Boston Marathon bombing and most recently the flooding in Houston and formed the basis for the WHO guide for hospital preparedness. At Brigham and Women’s and Partners Healthcare, bringing lessons of system response from emergency preparedness, he incorporated these modern industrial engineering and informatics principles into care redesign, access and clinical integration.

In 2012, Dr. Zane was recruited to the University of Colorado School of Medicine and Hospital as the inaugural chair of the department of emergency medicine where he led a massive redesign of emergency services. This successful redesign focused not only on integrating industrial engineering practices but also partnering with industry to integrate patient and data centric technologic solutions into the care process resulting in dramatic improvements in quality, experience and cost. UCHealth University of Colorado Hospital Emergency Department was recently ranked the #2 academic ED in the country by Vizient and this approach to care redesign has been replicated across the UCHealth system in 31 emergency departments, as well as the departments of radiology, surgery, oncology and critical care medicine. UCHealth University of  Colorado Hospital has been visited by over 50 health care systems from across the United States, Europe and Asia where fundamental principles of this approach to care redesign are being emulated and Dr. Zane has been asked to consult for the National Health Service in the UK and Ireland as they grapple with emergency care redesign.

As Chief Innovation Officer for UCHealth, Dr. Zane is focused on the development of novel industry and venture relationships to bring innovative solutions to health care. By partnering with companies, from small start-ups to multinationals, and using the power of data science, remote monitoring and prescriptive intelligence, he is attempting to fundamentally alter and improve the way in which health care is delivered.

In 2016, Dr. Zane co-founded the UCHealth CARE Innovation Center in partnership with CU Innovations. The CARE Innovation Center is the UCHealth clinical-validation sandbox that helps company partners test, pilot, optimize and commercialize the most innovative new technologies in health care. CARE Innovation specializes in fundamentally changing the way health care is delivered to patients and seeks partnerships with digital health companies that challenge the status quo.

Dr. Zane has been widely published in peer reviewed publications, his work has been featured in the Harvard Business Review and Wall Street journal and he was recently named a New England Journal of Medicine Catalyst Thought Leader in Medicine.
 

Contact Information:

Eric A. Klein, MD is the Andrew C. Novick Distinguished Chair of  the Glickman Urological and Kidney Institute and Professor of Surgery in the Lerner College of Medicine of the Cleveland Clinic. Following undergraduate training at Johns Hopkins University, he was a cum laude graduate of the University of Pittsburgh School of Medicine. He subsequently completed residency training in Urology at the Cleveland Clinic and a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center. He joined the staff of the Cleveland Clinic in 1989 and currently serves as a member of the Department of Cancer Biology of the Cleveland Clinic Lerner Research Institute, the Taussig Cancer Institute, and the Genitourinary Malignancies Program in the Case Comprehensive Cancer Center.
 
Dr. Klein is a member of numerous professional societies and scientific advisory boards including the Board of Scientific Counselors – Clinical Sciences and Epidemiology of the National Cancer Institute, the American Association of Genitourinary Surgeons, the Clinical Society of Genitourinary Surgeons, the Society of Urologic Oncology, the Society of Pelvic Surgeons, the American College of Surgeons, the American Society of Clinical Oncology, and the American Urological Association. He served as President of the Society of Urologic Oncology from 2009 - 2011.
 
Dr. Klein’s clinical and research interests cover all stages of prostate cancer with a focus on genomics and clinical trials. He was the National Study Coordinator for the NCI-sponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT) and has contributed more than 600 papers to the scientific literature, authored or edited 8 books on urologic malignancies, and serves as the Editor-in-Chief of Urology. He has delivered more than 200 invited scientific lectures including 13 named lectureships, and has served as a Visiting Professor at more than 60 institutions around the world. Dr. Klein was awarded the F. Mason Sones Innovation Award by the Cleveland Clinic in 2009, The Joe V. Meigs Award by the Society of Pelvic Surgeons in 2013 and 2015, was named the Kidney Foundation of Ohio’s Person of the Year in 2017, and has received 5 Career Achievement Awards including a 2014 Presidential Citation from the American Urological Association,  the 2014 Huggins Medal from the Society of Urologic Oncology, the 2015 Philip S. Hench Award from the University of Pittsburgh School of Medicine, the 2020 SUO Medal from the Society of Urologic Oncology, and the 2020 Richard D. Williams, MD Prostate Cancer Research Excellence Award from the Urology Care Foundation. He is currently co-leader of the Cleveland Clinic Lerner Research Institute-designated Prostate Cancer Center of Excellence.
 

Contact Information:

Safra A. Catz has served as chief executive officer of Oracle Corporation since 2014 and a member of the company's board of directors since 2001. She previously served as president of ORacle and has also serves as the company's chief financial officer. Prior to beign named president, Catz held various other positions since starting at ORacle in 1999. She currently serves as a director of The Walt Disney Company and previously served a director of HSBC Holdings plc.

Contact Information:

Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.

Mr. Bancel currently serves on the board of directors of Qiagen N.V. and previously served on the board of directors of BG Medicine, Inc. and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.

Contact Information:

Steven M. Gordon, MD, Chairman and Staff Member in the Department of Infectious Disease and a Staff Member in the Transplantation Center.

He is certified in Internal Medicine, as well as Infectious Disease by the American College of Physicians. His specialty interests include healthcare epidemiology, infective endocarditis, and cardiac device infections

Dr. Gordon earned his medical degree from Cornell University Medical College in New York. He completed an internship and residency in Internal Medicine at the University of Chicago Hospitals and Clinics in Chicago, as well as a residency with the U.S. Public Health Service. He was a Fellow with the Centers for Disease Control, Hospital Infections Program, as well as a Fellow with Emory University Hospital in Atlanta, Ga.

He is a member of several professional organizations, including the Society Healthcare Epidemiology of America  for which served as President of the society (January 2011). He is a Fellow of the Infectious Disease Society of America, a Fellow of the American College of Physicians, and member of  American Society of Transplantation. Dr. Gordon has received a number of honors and awards over the years.  Most recently, he was appointed to serve on the Defense Health Board which serves as a Federal Advisory Committee to the Secretary of Defense.  He has also presented a number of national and international meetings, as well as having published more than 160 articles and multiple book chapters.

Contact Information:

Susan completed her Bachelor of Science in Microbiology from the University of Illinois, C-U and her Master of Business Administration from the University of Nebraska. Susan has more than 30 years of manufacturing experience, including energy, automotive vehicle, powertrain and components assembly. Susan has dedicated her career to improving American manufacturing and assuring that the United States maintains a vital manufacturing footprint, especially in areas of key technological advances. In her time as a manufacturing practitioner, she has always been a strong proponent of sustainability, starting in her first role as the Environmental and Coating Manager with Douglas and Lomason, leading the plant to the State of Iowa's first ever Waste Minimization award to launching the all-electric Nissan Leaf in Smyrna, TN and now the COO of Bloom Energy, in Sunnyvale, CA, bringing reliable #alwayson energy to critical infrastructure including Data Centers, Hospitals, Grocery stores, banks and other essential services. Throughout her career, she has maintained that jobs and the environment can have a symbiotic relationship, and that passion drives her as she pursues her role at Bloom. In addition, she has created and supported organizations that encourage young women to pursue careers in math and science as a way to support future generations of technological manufacturing in the United States. Susan founded Southern Automotive Women’s Forum, a 10 year old 501c3 whose mission to provide professional development for women in automotive and scholarships has changed the face of automotive leadership in the Southeast United States.  Susan is now an ambassador for C3E, a Dept of Energy program tasked with bringing more women into Energy and for professional development of women currently in the energy field.  Both of these organizations support Susan’s passion of building and growing technical fields to be more open and accessible for highly talented and skilled women.
 
Susan shared the story of her career with her Alma Mater, University of Illinois, giving the Molecular and Cellular Biology Commencement speech in 2019 to tell her story of how a technical degree can have a rewarding and exciting path for those who are willing to take on the challenge.
 

Contact Information:

Toby Enqvist is the senior vice president and chief customer officer at United. He is responsible for overseeing our inflight services, corporate real estate, contact centers and customer care, customer strategy and innovation, and customer experience and analytics. 

Toby has been in the airline industry for over 24 years, joining Continental in 1996. During these 24 years with Continental and United Airlines, Toby has held several senior leadership positions within operations and finance. Toby was most recently senior vice president of network operations and customer solutions for United. In addition to overseeing the day-to-day operations of the airline in the areas of operational control, he was and still is responsible for overseeing contact centers and customer care teams. Another part of his past and current experience is developing and giving our front-line employees the tools, policies and processes needed to succeed at their jobs on a daily basis.

Born and raised in Stockholm, Sweden, Toby moved to the U.S. to attend Ouachita Baptist University on a tennis scholarship, where he earned his bachelor’s degree in business administration. He received his Master of Business Administration from Southern Methodist University in Dallas, Texas. He is also a member of the Northwestern University Business Advisory Council. He is married and has a daughter.

Contact Information:

Tom Lawry serves as National Director of AI for Health & Life Sciences at Microsoft and previously served as Director of Worldwide Health. Tom works with providers, payors and life science organizations in planning & implementing innovative analytical solutions that improve the quality and efficiency of health services delivered around the globe.

Tom focuses on strategies for digital transformation applied to performance optimization including Artificial Intelligence (AI), Machine Learning (ML) and Cognitive Services.  He previously served as Director of Organizational Performance for Microsoft’s health incubator (Health Solutions Group).

Prior to Microsoft Tom served as a Senior Director at GE Healthcare with global responsibilities for revenue cycle management analytics and operational performance solutions.

Lawry was founder and CEO of Verus, a healthcare software company named as one of the Top 100 Fastest Growing Washington Companies for three consecutive years and to the Deloitte Fast 500 Technologies list.
For twelve years Lawry served in various executive management roles in hospitals and integrated delivery networks. He has published numerous articles on topics relating to use technology to innovate healthcare. His new book from HIMSS & CRC Press is: Artificial Intelligence in Healthcare: A Leader’s Guide to Winning in the New Age of Intelligent Health Systems.


 

Contact Information:

Tom Mihaljevic, MD, is CEO and President of Cleveland Clinic. He leads an $8 billion medical system that includes a main campus, 10 regional hospitals, 18 family health centers, and facilities in Florida, Nevada, Toronto, Abu Dhabi and London. Representing a new generation of leadership for American’s #2 ranked hospital (U.S. News & World Report), Dr. Mihaljevic seeks to build on Cleveland Clinic’s reputation for medical expertise, to enhance the patient experience, and expand access to clinical services. Dr. Mihaljevic joined Cleveland Clinic in 2004 as a surgeon in the Department of Thoracic and Cardiovascular Surgery. He has performed almost 3,000 operations over the course of his career, specializing in minimally invasive and robotic-assisted procedures, valve replacement and repair, image-guided surgery, heart failure and cardiac transplantation. He earned his medical degree at the Medical School, University of Zagreb, Croatia. He trained in cardiac surgery at the University of Zurich, Switzerland. In the United States, he did residencies in general and cardiothoracic surgery at Brigham and Women’s Hospital, and was chief resident in the Department of Cardiovascular Surgery at Boston Children’s Hospital. Before coming to Cleveland Clinic, Dr. Mihaljevic was director of the Cardiac Surgery Research Laboratory and an associate surgeon in the Division of Cardiac Surgery at Brigham and Women’s Hospital in Boston. Dr. Mihaljevic held a seven-year academic appointment to Harvard Medical School as a Clinical Fellow in Surgery. He was also Assistant Professor of Surgery at Harvard Medical School. From 2015-2017, Dr. Mihaljevic served as CEO of Cleveland Clinic Abu Dhabi (CCAD). He oversaw the opening of the 365-bed hospital and clinic, with 3,000 caregivers, in 2015. Under his leadership, CCAD expanded its treatment capabilities, built relationships in the private and public sector, and established its growing reputation for clinical excellence, research and education. From 2010 to 2015, Dr. Mihaljevic was Chief of Staff and Chairman of the Heart & Vascular Institute at CCAD. He led a recruitment effort that drew 5,500 applications for 175 physician posts, and went on to launch the most advanced cardiovascular program in the Middle East.

Contact Information:

Dr. William Morris is the Executive Medical Director of Cleveland Clinic Innovations. Dr. Morris has been a staff member of Hospital Medicine at Cleveland Clinic since 2006. In his former role as Associate Chief Information Officer he had oversight of design, development, and deployment of all clinical IT systems and health IT innovations. Dr. Morris also continues to practice medicine, and in 2017 was elected to Board of Governors on which he currently serves.

Dr. Morris earned his medical degree from Case Western Reserve University School of Medicine and completed training in Internal Medicine at Beth Israel Deaconess Medical Center, Harvard Medical School. He also received his MBA in 2017 from Case Western Reserve University Weatherhead School of Management.

Contact Information: